(PDP)(UH2/UH3) http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-11-015.html
RFA-DA-11-015
Letter of Intent Due Date: March 26, 2011
Application Due Date: April 26, 2011 by 5:00PM local time of applicant organization
FOA Purpose:
The National Institute on Drug Abuse (NIDA) invites cooperative agreement applications from qualified non-profit, private and academic researchers/organizations to participate in the planning and execution of a new public-private partnership (PPP). The purpose of a one-year planning phase (UH2) is to provide support for the systematic study directed toward fuller scientific understanding of the opportunities in the area of drug discovery and development for tobacco dependence, with the ultimate goal of establishing a PPP, specifically, a Product Development Partnership (PDP). The mission of the PDP is to develop safe and effective medications for the treatment of tobacco dependence, including aids for smoking cessation. Phase two (UH3) funding will be utilized to support the implementation and execution phase of the PDP, with one selected cooperative agreement recipient assuming the role of the PDP's Managing Partner. In this subsequent phase, the PDP will conduct a wide array of research and development (R&D) projects aimed at the fulfillment of regulatory requirements for approval for marketing in the US.
See announcement for complete information http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-11-015.html
Please send inquiries to Medications Initiative for Tobacco Dependence: NIDAMedTDWG@mail.nih.gov or call 301-443-9800
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services
TO UNSUBSCRIBE: send email to listserv@list.nih.gov, Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email
- You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment